株式会社極東書店トップ > 商品一覧 > Neoliberalism, State-Corporate Power and Regulatory Failure : The Harms of Prescription and Non-Prescription Medicine Regulation in Australia.
商品詳細
Neoliberalism, State-Corporate Power and Regulatory Failure : The Harms of Prescription and Non-Prescription Medicine Regulation in Australia.
・ISBN 978-1-032-25943-7 hard GB£ 171.99
¥54,486.- (税込) ※(※)価格はご注文時の参考価格となります。
納品価格につきましては書籍の入荷時点で確定となります。
版元の原価改定、外国為替の変動等により異なる場合がございますので、予めご了承下さい。
電子版あり 大学・学術機関向け電子ブック(eBook)ISBN 978-1-003-28576-2
| 著者・編者 | Bandiera, Rhiannon, |
|---|---|
| シリーズ | Routledge Studies in Crime and Society |
| 出版社 | (Routledge, UK) |
| 出版年月 | 2025.05 |
| ページ数 | 226 pp. |
| 言語 | ENG |
| ニュース番号 | <742-172 742-341> |
解説
Based on over a decade of research, this book examines the social harms of Australian prescription and non-prescription medicine regulation and how these ultimately stem from neoliberalism and its reinforcement of state and corporate power.
Neoliberalism shapes state and corporate power, regulation and the harms resulting from regulatory failure, yet the links between these themes are rarely discussed. Drawing on the concept of hegemonic neoliberal governmentality, this book critically examines Australian medicine regulation and the harms resulting from its failure in areas such as medicine quality, safety and efficacy; direct-to-consumer advertising; and marketing directed at health professionals. It traces these harms through the colonial foundations and evolution of medicine regulation in Australia, exploring both regulatory failure and the attempts at reforming this regulatory system. It argues that neoliberalism is not regulatable and reinforces and sustains itself, empowering the state and corporations while disempowering the public and those representing its interests. Thus, reducing its harms is only achievable through broader, transformative change, rather than by reforming (and thereby continuing to work within) the existing neoliberal capitalist system.
Neoliberalism, State-Corporate Power and Regulatory Failure will be of value to practitioners, members of the public and private sector and academics active in the fields of state, corporate and state-corporate crime, social harm and regulation, as well as to those new to the study of medicine-related harms. It will also be of interest to all those concerned about their health and the medicines they use.